AGP Executive Report
Last update: 11 hours agoUS Pharma Tariffs, Liechtenstein in the mix: The US Commerce Department has published a Federal Register list exempting certain specialty medicines and key ingredients from a planned 100% ad valorem tariff, with eligibility tied to specific product categories (rare diseases, fertility, cell/gene therapies, antibody-drug conjugates, nuclear medicines, plasma-derived therapies, and some animal health) and to qualifying trade/security frameworks; Liechtenstein is named among the 20 jurisdictions getting the 0% rate. US Guidance for companies: US Customs and Border Protection also issued updated Section 232 guidance clarifying how the pharmaceutical tariff regime and duty-free treatment will be applied, but exemptions are not automatic and require product-level compliance. Local health workforce rules (Ireland, but relevant for care capacity): A “50:50 rule” limiting non-EEA workers is being temporarily relaxed to tackle healthcare staffing shortages, especially in nursing homes, home-care, and disability services. Reproductive rights debate in Liechtenstein: The European Evangelical Alliance raised concerns after Liechtenstein’s parliament narrowly backed a citizen-led initiative to legalize abortion in the first 12 weeks. EU drug access milestone: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for early cerebral adrenoleukodystrophy (cALD), with launches expected to begin in Germany.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
